Navigation Links
European Multidisciplinary Conference in Thoracic Oncology -- press program
Date:2/23/2011

The following studies will be presented in the Press Program of the second European Multidisciplinary Conference in Thoracic Oncology, a multipartner initiative for physicians of all medical disciplines dealing with lung cancer and other thoracic malignancies.

The full text of the embargoed press releases/abstracts can be requested to the EMCTO Press Office at media@esmo.org. When the embargo lifts, the texts will be available in the ESMO Online Newsroom.

  1. Quick, easy test identifies aggressive type of lung cancer in never-smokers (embargo: 25 February 2011, 8:00 CET)
    Inexpensive and rapid test can effectively identify sub-group of never-smoking lung cancer patients whose tumors express molecule associated with increased risk of disease progression or recurrence.
    Author: Ping Yang, US

  2. Oncogene AEG-1 strongly predicts response to erlotinib treatment in EGFR-mutant lung cancer (embargo: 25 February 2011, 8:00 CET)
    Researchers identified a gene whose expression level strongly predicts how well and how long certain lung cancer patients will respond to treatment with erlotinib.
    Author: Rafael Rosell, Spain

  3. Bone drug zoledronic acid may help prevent spread of early lung cancer (embargo: 25 February 2011, 8:00 CET)
    Drug currently used to help treat bone metastases in patients with lung cancer could also be useful at an earlier state of treatment to prevent cancer from spreading.
    Author: Michela Quirino, italy

  4. Radio-guided surgery, a safe and simple way to remove potentially cancerous nodules in the lung (embargo: 26 February 2011, 8:00 CET)
    Using tiny spheres of radioactive liquid to guide surgeons as they remove potentially cancerous material in the lungs is safe and more effective than other techniques.
    Author: Luca Bertolaccini, Italy

  5. Phase III trial: erlotinib as effective as chemo, with fewer side-effects, in patients whose disease progressed after first-line treatment (embargo: 26 February 2011, 8:00 CET)
    Targeted cancer drug erlotinib has comparable efficacy to chemotherapy and is better tolerated in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy.
    Author: Tudor Ciuleanu, Romania


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. IOF calls on European citizens to stand tall and speak out for their bones
2. IronKey Opens New European Office
3. European researchers harness unique properties of boron to develop new drugs and diagnostics
4. Vidaza receives positve opinion from European CHMP
5. The MDS foundation supports vidazas recommendation for European approval
6. European biodiversity and ecosystem scientists merge and gear up for long-term research
7. Overfishing threatens European bluefin tuna
8. European ancestry increases breast cancer risk among Latinas
9. IRB Barcelona to coordinate two European projects on biomedicine
10. Key to future medical breakthroughs is systems biology, say leading European scientists
11. Global warming linked to European viral epidemic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... public,s help is being enlisted in what,s thought to be the biggest ... human body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest study to date ... project's goal is to help advance scientific knowledge of the role of ... The ...
(Date:6/30/2017)... Va. , June 30, 2017 ... leading developer and supplier of face and eye ... ATA Featured Product provider program. ... an innovative way to monitor a driver,s attentiveness ... greatly from being able to detect fatigue and ...
(Date:5/23/2017)... , May 23, 2017  Hunova, the first robotic gym for ... has been officially launched in Genoa, Italy . The ... and the USA . The technology was ... the market by the IIT spin-off Movendo Technology thanks to a 10 ... Multimedia News Release, please click: ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... ... October 10, 2017 , ... ... 13 prestigious awards honoring scientists who have made outstanding contributions to ... symposium during Pittcon 2018, the world’s leading conference and exposition for laboratory science, ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board ... Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been selected ... member of the winning team for the 2015 Breakthrough Prize in Fundamental physics for ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... and applications consulting for microscopy and surface analysis, Nanoscience Instruments is now ... Analytical offers a broad range of contract analysis services for advanced applications. ...
(Date:10/6/2017)... ... October 06, 2017 , ... ... healthcare and technology sector at their fourth annual Conference where founders, investors, innovative ... speakers and the ELEVATE pitch competition showcasing early stage digital health and med ...
Breaking Biology Technology: